Purchasing a Product Candidate. If AstraZeneca wishes to file an IND for a Product Candidate but at the time of such filing forty (40) Product Candidates [***] forty (40) Development Polypeptides are being further Developed or Commercialized in accordance with the Commercialization Schedules, the Parties will discuss in good faith how AstraZeneca may purchase the right to continue to Develop and Commercialize an additional Product Candidate for a purchase price equal to the fair market value of such Product Candidate (which purchase price will include at a minimum an initial payment of [***])). There will not be more than [***] of such purchases.
Appears in 4 contracts
Sources: Option Agreement (Moderna, Inc.), Option Agreement (Moderna, Inc.), Option Agreement (Moderna, Inc.)